Jarlath serves as President & Chief Executive Officer of ABL and as a member of the Board of Directors. Jarlath was appointed CEO in October 2018 having previously served as Chief Commercial Officer when he joined ABL in August 2018.
Jarlath brings over 25 years of global industry experience to ABL, starting his career in the United Kingdom before transitioning to the United States in 2009. Over this time, he has successfully helped companies grow and realize their potential in a variety of life science focused organizations.
Prior to joining ABL, Jarlath served as the Vice President of Global Commercial Operations for MilliporeSigma’s Process Solutions Services division, leading the BioReliance® biological safety testing and biomanufacturing services divisions. In this role, he oversaw the aggressive expansion of services to customers in North America, Europe and Asia Pacific, spending a total of 12 years with the BioReliance organization.
Jarlath has also held commercial leadership positions with HyClone, where he spent 4 years focusing on bioprocessing consumables and Life Technologies where he spent 3 years in international sales. Jarlath started his career at Lonza Biologics and the Agriculture & Food Research Council in a technical capacity.
Jarlath holds a Bachelor of Science Degree in Process Biotechnology from the University of Teesside in the UK and a CBA from Georgetown University.